![Eurofins-Cerep SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png?tr=w-200)
Eurofins-Cerep SA
PAR:ALECR
![Eurofins-Cerep SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png)
Intrinsic Value
The intrinsic value of one
ALECR
stock under the Base Case scenario is
20 724.22
EUR.
Compared to the current market price of 22 200 EUR,
Eurofins-Cerep SA
is
Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png?tr=w-200)
Valuation Backtest
Eurofins-Cerep SA
Run backtest to discover the historical profit from buying and selling
ALECR
based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
![](https://ik.imagekit.io/kkbzr2uz4cp/other/ai-assistant.png)
Revenue & Expenses Breakdown
Eurofins-Cerep SA
Balance Sheet Decomposition
Eurofins-Cerep SA
Current Assets | 61m |
Cash & Short-Term Investments | 9.3m |
Receivables | 46.8m |
Other Current Assets | 4.9m |
Non-Current Assets | 11.7m |
Long-Term Investments | 17k |
PP&E | 9.2m |
Intangibles | 2.2m |
Other Non-Current Assets | 237k |
Current Liabilities | 11m |
Accounts Payable | 4.5m |
Accrued Liabilities | 3.5m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 1.5m |
Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Eurofins-Cerep SA
Revenue
|
46.2m
EUR
|
Cost of Revenue
|
-6.7m
EUR
|
Gross Profit
|
39.5m
EUR
|
Operating Expenses
|
-31.3m
EUR
|
Operating Income
|
8.2m
EUR
|
Other Expenses
|
973k
EUR
|
Net Income
|
9.2m
EUR
|
Free Cash Flow Analysis
Eurofins-Cerep SA
EUR | |
Free Cash Flow | EUR |
ALECR Profitability Score
Profitability Due Diligence
Eurofins-Cerep SA's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png)
Score
Eurofins-Cerep SA's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
ALECR Solvency Score
Solvency Due Diligence
Eurofins-Cerep SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png)
Score
Eurofins-Cerep SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALECR Price Targets Summary
Eurofins-Cerep SA
Shareholder Yield
Current shareholder yield for ALECR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
ALECR Price
Eurofins-Cerep SA
Average Annual Return | 54.41% |
Standard Deviation of Annual Returns | 78.06% |
Max Drawdown | -27% |
Market Capitalization | 111.9m EUR |
Shares Outstanding | 5 000 |
Percentage of Shares Shorted |
N/A
|
Profile
![Eurofins-Cerep SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png?tr=w-200)
![Eurofins-Cerep SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/par/alecr.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALECR
stock under the Base Case scenario is
20 724.22
EUR.
Compared to the current market price of 22 200 EUR,
Eurofins-Cerep SA
is
Overvalued by 7%.